NASDAQ: CRME TSX: COM
VANCOUVER, Dec. 29 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX:
COM) today announced that it has been advised by its partner, Merck
(known as MSD outside the United States and Canada), that the current
review of vernakalant (oral) is complete, and